OncoMatch/Clinical Trials/NCT06769971
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
Is NCT06769971 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ivonescimab and Cadonilimab for small cell lung cancer.
Treatment: Ivonescimab · Cadonilimab · Etoposide · Carboplatin — This is a phase II study. All patients are treatment naive extensive stage small cell lung cancer(ES-SCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of Ivonescimab and Cadonilimab in combination with chemotherapy in patients with ES-SCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Exception: ES-SCLC patients who had received definitive chemoradiotherapy for limited-stage small-cell lung cancer but had disease progression > 6 months earlier
Had not received previous systemic therapy; Or ES-SCLC patients who had received definitive chemoradiotherapy for limited-stage small-cell lung cancer but had disease progression > 6 months earlier
Cannot have received: immunotherapy targeting tumor immunity
Subjects who received any prior treatments targeting the mechanism of tumor immunity
Cannot have received: anti-angiogenic therapy
Subjects who received any prior anti-angiogenic therapy
Cannot have received: palliative local treatment
Received palliative local treatment within 2 weeks prior to the first dose
Cannot have received: non-specific immunomodulatory treatment
non-specific immunomodulatory treatment within 2 weeks prior to the first dose
Cannot have received: Chinese herbal medicine or traditional Chinese medicinal products with anti-tumor indications
Chinese herbal medicine or traditional Chinese medicinal products with anti-tumor indications within 1 weeks prior to the first dose
Lab requirements
Blood counts
Kidney function
Liver function
Have adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify